October 14, 2022/ Luxembourg: On Oct 14^th 2022, the Hon. Prime Minister of Luxembourg, Mr. Xavier Bettel, visited B Medical Systems, a leading global provider of medical cold chain solutions in Hosingen, Luxembourg. During the visit, the Hon. Prime Minister Mr. Xavier Bettel interacted with the management team and the employees of the company, learning about the company’s technological and manufacturing capabilities and global expansion plans; and discussing the significant impact of B Medical Systems on Luxembourg’s economy and in vaccinating the world.

B Medical Systems was recently acquired by Azenta, Inc., a leading provider of unrivaled sample exploration and management solutions to help accelerate discovery, development, and delivery of life-saving therapies. The President and CEO of Azenta, Dr. Stephen S. Schwartz, accompanied the Prime Minister, along with Mr. Luc Provost, the CEO of B Medical Systems, and Mr. Jesal Doshi, the Deputy CEO of B Medical Systems.

“During the COVID-19 pandemic, B Medical’s products made their way around the entire world. Luxembourg, however, has known the important value of these products well before the start of the pandemic. I congratulate B Medical once more on their recent expansion to India. Today, I am glad to notice that the innovation spirit within the company is developing even faster – a spirit that is very well aligned with Luxembourg,” said Mr. Xavier Bettel, the Hon. Prime Minister of Luxembourg.

“We are excited that B Medical Systems is now part of our growing portfolio of offerings. B Medical Systems has done an outstanding job of carving out a strong market position in the vaccine cold chain, and we see opportunities to drive even further value by leveraging the Azenta platform,” said Dr. Steve Schwartz, President and CEO of Azenta.

“The Grand Duchy of Luxembourg has played a crucial role in shaping us as a major player in the global medical cold chain landscape. The support we have received from the Government of Luxembourg has been incredible and has helped us effectively optimize our business model and facilities. Recent examples are our facility expansion in Luxembourg and the new subsidiary in India, where the Hon. Prime Minister himself played a crucial role. I am confident that we will be able to significantly expand our global impact further as part of the Azenta family and with the support of the Govt. of Luxembourg,” said Mr. Luc Provost CEO of B Medical Systems.

B Medical Systems has been supplying medical cold chain products across the world from Luxembourg for the last 40 years. The company relies on the country’s strategic location, workforce, and transportation infrastructure for the quick delivery of products worldwide. B Medical Systems’ ultra-low freezers, vaccine refrigerators/freezers, laboratory refrigerators/freezers, and transport boxes were extensively used across the world during the COVID-19 pandemic. The company has provided more than 70,000 cold chain units to 140+ countries for their effective COVID-19 immunization programs. B Medical Systems was also the exclusive supplier of Luxembourg’s COVID-19 vaccine cold chain solution.

“Safe Harbor Statement” under Section 21E of the Securities Exchange Act of 1934

Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta’s financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include but are not limited to statements about the expected growth and market penetration of the B Medical Systems business. Factors that could cause results to differ from our expectations include the following: the continued market acceptance of the Company’s products, including B Medical products, the volatility of the life sciences industries the Company serves, and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, current reports on Form 8-K and our quarterly reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.